Ra Capital Management, L.P. Inhibrx, Inc. Transaction History

Ra Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$32.76 - $39.56 $68.6 Million - $82.9 Million	-2,094,370 Reduced 44.33%	2,629,837 $91.9 Million
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $68.5 Million - $180 Million	4,724,207 New	4,724,207 $180 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $13.7 Million - $22.9 Million	870,340 Added 22.58%	4,724,207 $86.7 Million
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $77.8 Million - $128 Million	3,853,867 New	3,853,867 $95 Million
Q1 2021 May 17, 2021	SELL	$16.27 - $41.26 $34.6 Million - $87.8 Million	-2,129,003 Closed	0 $0

Q3 2020 Nov 16, 2020	BUY	$16.77 - $20.65 $35.7 Million - $44 Million	2,129,003 New	2,129,003 $38.3 Million

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $589M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.